Narrative review of the staging classification controversy in stage N3 small cell lung cancer: from the perspective of overlapping Veterans Administration Lung Study Group and International Association for the Study of Lung Cancer definitions Authors: Xinyu Chen, Qilin Wang, Juncai Ye, Xueping Yang, Jiahao Chen, Guangzeng Zhou, Chuanyu You, Tian Xu, Yan Gui Published: 2026 ABSTRACT Background and ObjectiveTraditionally, two primary systems have been employed for staging small cell lung cancer (SCLC): the Veterans Administration Lung Study Group (VALG) system and the International Association for the Study of Lung Cancer (IASLC) tumor, node, metastasis (TNM) system. The term “limited disease” is defined differently: VALG characterizes it as disease encompassed within a single tolerable radiation field, while IASLC defines it as the lack of distant metastases (M0). Patients with N3 disease frequently satisfy VALG extensive-stage (ES) criteria while meeting IASLC limited-stage (LS) criteria, resulting in a notable staging discrepancy. Therefore, this review aims to clarify the clinical challenges posed by this staging overlap and provide insights for standardizing staging terminology and optimizing therapeutic decision-making in N3 SCLC.MethodsA narrative review utilizing a systematized search strategy was conducted. While strict adherence to PRISMA guidelines was not pursued because the extensive heterogeneity of the literature precluded a formal meta-analysis, rigorous search criteria were applied to minimize selection bias. Databases including PubMed, Web of Science, Embase, the Cochrane Library, and China National Knowledge Infrastructure (CNKI) were searched for literature from January 2000 to March 2026. Studies examining stage N3 SCLC, spatial metastatic burden, and definitional inconsistencies between the VALG and IASLC staging systems were analyzed to assess their effects on treatment dosimetry, systemic therapy, and survival outcomes.Key Content and FindingsThe staging overlap in N3 SCLC leads to heterogeneous clinical management depending on its spatial metastatic burden, and this highly variable cohort can be stratified into distinct prognostic subgroups based on the anatomical distribution (single-region vs. multi-region) of the involved lymph nodes.ConclusionsThese findings should guide clinical trial design and terminology. Clinical decision-making must transcend historical paradigms and technical constraints. Future strategies must incorporate spatial evaluations of metastatic burden alongside innovative multimodal tools, such as artificial intelligence (AI) and multi-omics, to facilitate tailored therapy for SCLC. Introduction Background Comprising approximately 15% of all lung cancers, small cell lung cancer (SCLC) is a neuroendocrine tumor characterized by high aggressiveness, rapid proliferation, and early distant metastasis. Notably, approximately two-thirds of patients present with extensive-stage (ES) disease at initial diagnosis, resulting in a generally poor prognosis (1). Accurate staging of SCLC is essential for guiding treatment strategies; typically, patients with early-stage disease receive curative-intent combination chemoradiotherapy, whereas those with advanced disease primarily undergo systemic therapy (2). Since the 1950s, the binary limited-stage (LS) and ES categorization introduced by the Veterans Administration Lung Study Group (VALG) has been widely utilized due to its simplicity and clinical convenience (3). Concurrently, the tumor, node, metastasis (TNM) staging system, initially designed for non-small cell lung cancer (NSCLC), has been progressively adapted for SCLC and formally endorsed by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC). Rationale and knowledge gap Although both systems are utilized extensively in clinical practice, their definitions of “LS” differ fundamentally. The VALG criteria emphasize the technical feasibility of incorporating the tumor within a tolerable radiotherapy field, whereas the IASLC criteria focus on the anatomical extent of the disease in the absence of distant metastasis (4). This definitional discrepancy creates an overlapping cohort of patients who are categorized as having ES disease by VALG criteria, yet classed as having LS disease according to IASLC guidelines. Patients with stage N3 lesions constitute the core of this controversial overlapping area. Objective Therefore, this narrative review aims to elucidate the fundamental attributes of this staging overlap. Ultimately, we seek to provide a foundation for standardizing staging terminology, optimizing inclusion criteria for clinical trials, and facilitating personalized treatment strategies for patients with SCLC. We present this article in accordance with the Narrative Review reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1704/rc). Methods Search strategy and selection criteria A narrative review utilizing a systematized search strategy was performed. This hybrid methodological approach was deliberately chosen; while the profound methodological heterogeneity across N3 SCLC literature—such as disparate staging criteria and treatment modalities—precluded a formal quantitative meta-analysis and standard PRISMA compliance, applying systematized inclusion and exclusion criteria via two independent reviewers ensured a comprehensive, objective collection of evidence and minimized subjective cherry-picking. A comprehensive search of PubMed, Web of Science, Embase, the Cochrane Library, and the China National Knowledge Infrastructure (CNKI) was conducted for pertinent English- and Chinese-language literature. A timeframe from January 2000 to March 2026 was designated for the investigation of staging systems and recent therapeutic advancements. Utilizing the aforementioned sources, keywords including “small cell lung cancer” “SCLC” “N3 stage” “VALG” “IASLC” “limited stage” “extensive stage” “staging overlap” and “metastatic burden” were employed, alongside Boolean operators “AND” and “OR” to thoroughly gather research articles pertinent to the staging discrepancies and clinical management challenges of N3 SCLC. A detailed summary of the search strategy is presented in Table 1, and a specific example of the search syntax utilized for the PubMed database is provided in Table S1. Table 1The search strategy summaryItemsSpecificationDate of searchMarch 31, 2026Databases searchedPubMed, Web of Science, Embase, the Cochrane Library, and CNKISearch terms usedKeywords included “small cell lung cancer”, “SCLC”, “N3 stage”, “VALG”, “IASLC”, “limited stage”, “extensive stage”, “staging overlap”, and “metastatic burden”. These were employed alongside Boolean operators “AND” and “OR” (the detailed search strategy for PubMed is presented in Table S1)TimeframeJanuary 2000 to March 2026Inclusion and exclusion criteriaInclusion criteria: English and Chinese-language literature; studies with conclusively diagnosed SCLC patients; studies specifically examining the N3 staging category, geographical metastatic burden, or the definitional overlap between VALG and IASLC criteria; studies documenting clinical therapies, dosimetric restrictions, or survival results; exclusion criteria: non-SCLC focus studies, fundamental research or animal studies, single-case reports, conference abstracts lacking adequate quantitative data, letters, editorials, and duplicate publicationsSelection processTwo separate reviewers evaluated titles and abstracts to assess the relevance of studies. They subsequently examined the entire texts of the selected papers. The selection was conducted independently, and any discrepancies were addressed and resolved through consensusAdditional considerationsStrict adherence to PRISMA guidelines was not pursued because the extensive heterogeneity of the literature—such as disparate staging criteria and treatment modalities—precluded a formal quantitative meta-analysisCNKI, China National Knowledge Infrastructure; IASLC, International Association for the Study of Lung Cancer; SCLC, small cell lung cancer; VALG, Veterans Administration Lung Study Group. The search strategy summary CNKI, China National Knowledge Infrastructure; IASLC, International Association for the Study of Lung Cancer; SCLC, small cell lung cancer; VALG, Veterans Administration Lung Study Group. The subsequent studies were incorporated into the selection process: they conclusively diagnosed individuals with SCLC, specifically examined the N3 staging category, geographical metastatic burden, or the definitional overlap between VALG and IASLC criteria, and documented clinical therapies, dosimetric restrictions, or survival results. The following were excluded: NSCLC focus studies, fundamental research or animal studies, single-case reports, conference abstracts lacking adequate quantitative data, letters, editorials, and duplicate publications. Two separate reviewers evaluated titles and abstracts to assess the relevance of certain studies, thereafter examining the entire texts of the selected papers, with any discrepancies addressed and resolved through consensus. Data extraction A standardized data extraction form was employed to organize the fundamental information of the selected studies. The baseline data encompassed the study design, cohort size, patient demographic characteristics, distinct staging systems utilized across various institutions (VALG vs. IASLC), and other pertinent clinical variables; furthermore, critical clinical parameters such as the anatomical distribution of N3 lesions (single-region or multi-region involvement), specific treatment modalities, and primary prognostic indicators [e.g., median overall survival (OS)] were gathered. Synthesis of evidence Owing to significant methodological discrepancies across the included studies, including inconsistent staging standards, heterogeneous baseline metastatic burdens in patients, and various treatment modalities, a quantitative meta-analysis was unfeasible. A narrative synthesis of the evidence was done, with particular emphasis on elucidating the definitional distinctions between the VALG and IASLC systems and the consequent phenomena of “stage migration”. This narrative synthesis critically examined the impact of geographic metastatic burden on treatment decisions for N3 patients and established a basis for future precision staging utilizing multi-omics and artificial intelligence (AI). Historical evolution and core definition comparison of VALG and IASLC staging systems Origin, core definition and evolution of the VALG staging system Established in 1957 to evaluate the efficacy of combination chemoradiotherapy for patients with SCLC, the VALG staging system is founded on a fundamentally pragmatic core logic (5). LS refers to disease localized to one hemithorax, encompassing ipsilateral hilar, mediastinal, and supraclavicular lymph nodes, and amenable to treatment with a single “tolerable radiation port”. The ES encompasses diseases that have disseminated beyond these limits, including contralateral lung disease, contralateral hilar or mediastinal lymph node metastasis, contralateral supraclavicular lymph node involvement, malignant pleural or pericardial effusions, and hematogenous metastases. A characteristic aspect of this method is its “radiotherapy-oriented” approach; hence, the primary classification criteria are determined not by anatomical considerations but by the capacity to safely encompass all macroscopic disease inside a singular radiation field. A fundamental two-tier structure can facilitate prompt therapeutic decisions by physicians during the initial stages of a patient’s disease course. The working definition of a “tolerable radiation field” has evolved alongside advancements in radiotherapy technology. During the era of 2D radiation therapy, contralateral mediastinal metastases could not be safely treated. In recent years, advancements in precision technology have led to the introduction of intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT), enabling the safe treatment of numerous lesions previously deemed ineligible for single-port radiation therapy (6). The VALG system lacks the capacity to stratify the anatomical extent of lymph node metastases. Consequently, despite the considerable internal variability of N3 disease, all cases are routinely categorized as ES, thereby obscuring prognostic distinctions across patients with differing metastatic burdens. Evolution and core concepts of the IASLC TNM staging system The TNM staging system, endorsed by the IASLC, categorizes tumors anatomically into three components: T (primary tumor), N (regional lymph nodes), and M (distant metastases) (7). The latest edition of the TNM classification designates the N3 group as encompassing metastases to contralateral mediastinal or contralateral hilar lymph nodes, in addition to ipsilateral or contralateral scalene or supraclavicular lymph nodes. The IASLC defines LS disease as any lesion without distant metastasis (TxNxM0), and therefore, it is not restricted by the practicalities of radiotherapy field coverage; it categorizes limited and ESs solely based on the presence or absence of distant metastasis and malignant effusions (8). The nature of definitional differences and the mode of staging overlap The fundamental disparity between the two systems originates from their interpretations of “LS” disease: the VALG system is a technical criterion assessing the capability of contemporary radiotherapy apparatus to safely encompass all tumor locations, whereas the IASLC system pertains to a biological condition characterized by the absence of distant metastasis and malignant effusions. As radiotherapy technology advances, the “technical boundary” defined by the VALG criteria is evolving, although the “biological boundary” established by the IASLC has stayed mostly static. This alteration accounts for the staging overlap (9). Figure 1 below illustrates the rationale for the overlap in N3 lesions. In strict accordance with the original VALG criteria, contralateral mediastinal and hilar lymph node metastases, along with contralateral supraclavicular lymph node metastases, surpass the unilateral hemithorax and should consequently be categorized as ES disease. The IASLC standards categorize any disease lacking distant metastases (M0) as LS, regardless of the N description (10). Consequently, patients with N3M0 disease occupy a transitional status between the two classification stages, situated at the convergence of the VALG ES and IASLC LS systems. Moreover, ipsilateral supraclavicular lymph node metastasis is categorized as LS according to the VALG system (as it is confined to the ipsilateral hemithorax) and concurrently classified as N3M0 under the IASLC system; thus, it is universally acknowledged as LS disease by both systems. Owing to the disparate classifications, an identical patient may be categorized into varying prognostic groups in different clinical settings, resulting in heterogeneous therapies and consequently distinct survival outcomes (11). Staging classification overlap and clinical management of stage N3 SCLC subgroups. The NCCN guidelines classify TNM stages I–III as limited-stage disease, excluding T3–4 lesions with multiple pulmonary nodules or tumor volumes too large to be safely encompassed within a tolerable radiation field. Contralateral hilar and supraclavicular LN metastases are generally categorized as extensive-stage disease. ES, extensive-stage; IASLC, International Association for the Study of Lung Cancer; LN, lymph node; LS, limited-stage; M0, metastasis 0; N, node; NCCN, National Comprehensive Cancer Network; SCLC, small cell lung cancer; T, tumor; TNM, tumor, node, metastasis; VALG, Veterans Administration Lung Group. Diversity and inconsistency in the clinical management of N3 patients The initial ambiguity in the VALG staging system has resulted in heterogeneous treatment regimens for patients with N3 SCLC (12). Certain medical institutions rigorously follow the principle of “within a single radiotherapy field”, categorizing N3 patients with contralateral mediastinal or supraclavicular lymph node metastasis, who can be encompassed by one radiation field, as having “LS” disease and providing concurrent chemoradiotherapy (cCRT). In contrast, due to the poor prognosis conventionally associated with these N3 lesions, other centers have categorized them as “ES” and consequently implemented a primary treatment regimen of systemic chemoimmunotherapy (13,14). Consequently, patients in these two groups receive distinct treatment plans and are no longer comparable; thus, their clinical outcomes cannot be objectively assessed against one another. These divergent staging definitions are misaligned and, hence, cannot function as standard inclusion criteria for multi-center cooperative studies. For instance, most pivotal trials of cCRT specifically excluded patients with contralateral hilar or supraclavicular lymph node metastases in their design, thereby restricting the studies to a “pure” LS sample. Other trials allowed the inclusion of certain N3 patients, provided their lesions fell within the designated radiation field and were categorized as LS. To illustrate the profound impact of this definitional heterogeneity on study design, Table 2 summarizes the specific N3 inclusion and exclusion criteria across several landmark clinical trials in LS-SCLC, highlighting the historical transition from field-based technical constraints to TNM-based anatomical staging. These discrepancies in enrollment criteria suggest that the “LS” cohorts formed in diverse trials may exhibit varying degrees of baseline disease burden and prognostic outcomes; hence, bias could be incorporated into the clinical guidelines derived from these studies (15). The existing management challenge for SCLC patients with N3 disease indicates an urgent need for the refinement of the staging system and the establishment of a more precise prognostic classification (16). Table 2Heterogeneity of stage N3 inclusion/exclusion criteria in landmark clinical trials for LS-SCLCClinical trial/studyTarget populationSpecific inclusion/exclusion criteria regarding N3 lymph nodesImplication for N3 staging overlapADRIATIC (Spigel et al., 2024)LS-SCLC (consolidation immunotherapy)Inclusion: AJCC 8th Edition Stage I–III (M0). Explicitly included N3 disease (contralateral mediastinal/hilar or supraclavicular nodes) provided the total disease volume was amenable to definitive concurrent chemoradiotherapyUtilized precise anatomical TNM staging, recognizing M0 disease as LS-SCLC regardless of the N3 spatial burdenCONVERT (Faivre-Finn et al., 2017)LS-SCLC (standard vs. BID radiotherapy)Inclusion: disease restricted to one hemithorax, mediastinum, and supraclavicular nodes that could be safely encompassed within a radical radiotherapy volumeField-dependent criteria. Contralateral supraclavicular nodes were frequently excluded in practice if the required radiation volume exceeded safe dosimetric lung constraintsCALGB 30610/RTOG 0538 (Bogart et al., 2021)LS-SCLC (high-dose vs. standard radiotherapy)Inclusion: disease restricted to one hemithorax. Ipsilateral and contralateral supraclavicular nodes were allowed only if they could be safely encompassed within a single tolerable radiation portHighlighted the classic VALG technical constraint. High-burden multi-regional N3 patients were inherently excluded due to the inability to meet strict normal tissue dose constraintsRTOG 0239 (Phase II, 2012)LS-SCLC (prophylactic cranial irradiation)Exclusion: specifically and strictly excluded patients with contralateral hilar or contralateral supraclavicular lymph node involvementRepresented a highly restrictive interpretation of LS-SCLC, deliberately removing the high-risk N3 sub-population to maintain a “pure” localized cohortAJCC, American Joint Committee on Cancer; BID, bis in die; CALGB, cancer and leukemia group B; LS-SCLC, limited-stage small cell lung cancer; M0, metastasis 0; N3, node 3; RTOG, Radiation Therapy Oncology Group; TNM, tumor, node, metastasis; VALG, Veterans Administration Lung Group. Heterogeneity of stage N3 inclusion/exclusion criteria in landmark clinical trials for LS-SCLC AJCC, American Joint Committee on Cancer; BID, bis in die; CALGB, cancer and leukemia group B; LS-SCLC, limited-stage small cell lung cancer; M0, metastasis 0; N3, node 3; RTOG, Radiation Therapy Oncology Group; TNM, tumor, node, metastasis; VALG, Veterans Administration Lung Group. Role and prognostic value of N3 SCLC in the IASLC TNM stage staging system Value of N3 disease in terms of heterogeneity: a comparison of prognostic value at T4 and M1 stages This section aims to ascertain whether N3 SCLC constitutes an independent prognostic category distinct from T4 (locally advanced) or M1 (distant metastatic) disease, thereby enhancing the staging system. Traditionally, extensive-stage small cell lung cancer (ES-SCLC) encompasses all patients with M1 disease, whereas limited-stage small cell lung cancer (LS-SCLC) comprises those with T4 or N3 disease without distant metastasis; consequently, the prognosis of N3 disease (contralateral mediastinal or supraclavicular lymph node metastasis) must be evaluated in relation to T4 (invasion of vital organs) and M1 disease (17). According to the aforementioned findings, N3 disease is presumably an advanced stage of the condition with a significant probability of metastasis. Real-world studies indicate that N3 patients in the LS-SCLC cohort undergoing radical cCRT exhibit a median OS of 18–20 months. However, these real-world survival metrics must be interpreted with caution due to inherent selection bias. Patients selected for intensive radical cCRT typically possess a superior baseline performance status and fewer cardiopulmonary comorbidities compared to those triaged to palliative systemic therapy. This favorable baseline profile inherently inflates the observed survival outcomes, making direct comparisons with the broader ES-SCLC cohort partially confounded. While this is inferior to the OS of N0-2 patients, it markedly surpasses the OS of the conventional ES-SCLC (M1) group, which typically falls below 1 year (18). This prognostic distinction indicates that N3 patients have not yet seen significant hematogenous spread biologically, making them appropriate candidates for intense local treatment to prolong their survival. N3 disease fundamentally differs from pure anatomical invasion (T4); T4 generally entails invasion of adjacent tissues, such as major blood vessels or the esophagus, primarily resulting from local anatomical destruction and challenges in radiation port placement. In contrast, N3 signifies extensive dissemination into the lymphatic drainage system, accompanied by an elevated risk of distant occult micrometastasis (19). Figure 2 illustrates that N3 disease in SCLC represents an intermediate stage between local invasion and systemic dissemination; despite the potential for treatment with contemporary radiotherapy, it possesses a significantly elevated biological risk of systemic metastasis (20). Consequently, it is inappropriate to simply group the N3 stage with other locally advanced subgroups and apply a one-size-fits-all treatment protocol. The primary objective of this division is to identify a “grey area of patients” requiring both robust local consolidation therapy to manage local recurrence and extensive systemic treatment (e.g., chemoimmunotherapy) to avert hematogenous dissemination (21). By examining the various manifestations of N3 disease and eschewing a uniform approach, more customized, comprehensive, and multifaceted therapeutic strategies can be developed for this patient cohort. Biological continuum and prognostic stratification of N3 SCLC compared with T4 and M1 disease. M1, metastasis 1; N, node; SCLC, small cell lung cancer; T, tumor. Evaluation of the predictive accuracy of the TNM staging system for SCLC prognosis Given the restricted prognostic utility of the conventional dichotomous approach in VALG, the IASLC has advocated for the implementation of the TNM staging method for enhanced clinical stratification of SCLC. While the prognostic foundation for early-stage, operable SCLC is well-defined through accurate anatomical N-staging, such clarity has not been attained for advanced-stage disease. As the disease advances to a regionally advanced stage, the existing TNM system has been simplified to a binary variable (presence or absence) for the intricate N3 category, failing to represent the substantial disparity in survival within this group (22-24). Recent modifications to the N descriptors for NSCLC by the IASLC have transformed the foundational structure from an anatomy-centric system to one that quantifies metastatic burden, while also introducing subclasses such as N1a/b and N2a/b based on single vs. multiple involved lymph node stations. This data-driven approach is highly applicable to the management of SCLC and has been implemented in other contexts (25). The distribution of N3 lymph node involvement in the clinical progression of SCLC, whether confined to a singular metastatic site or extensively disseminated across multiple regions, more accurately indicates the extent of systemic dissemination and the status of the immune microenvironment than merely recognizing the presence of disease in the contralateral mediastinum or supraclavicular areas. Single-region metastasis may emerge from an initial disruption of the local lymphatic barrier; however, extensive multi-region dissemination is likely due to systemic lymphatic dysfunction and an increased likelihood of occult micrometastases (26). The anatomical heterogeneity of the N3 group has been overlooked, and the incorporation of a spatial burden index for SCLC N-stage stratification has not been executed. Consequently, the predictive accuracy of the TNM system will be enhanced, offering a novel approach to devise personalized therapies (e.g., pinpointing specific target areas for radiation therapy and augmenting the intensity of systemic treatment) for high-risk patients. Direct impact of the classification controversy on treatment decisions and patient prognosis Current application status and efficacy evidence of radical cCRT in N3 patients cCRT utilizing platinum and etoposide is now a recognized treatment for LS-SCLC (27). Nonetheless, owing to strict dosimetric constraints for N3 disease (characterized by contralateral mediastinal or supraclavicular extension), this protocol is often underutilized in practice. Due to the broad anatomical distribution of N3 disease, the planning target volume (PTV) will inherently be larger in comparison to early-stage cohorts. To maintain the total lung V20 (volume of lung receiving ≥20 Gy) and esophageal radiation doses within acceptable thresholds, some high-risk patients in clinical practice have been compelled to modify their treatment, transitioning to just systemic chemotherapy or palliative care. Nonetheless, the extensive utilization of sophisticated conformal methods like IMRT and VMAT has consistently enhanced the potential for intensified local interventions to yield survival advantages in this population (28,29). Research indicates that, following meticulous selection of N3 patients, those administered the complete dosage of cCRT exhibit a median OS of 18–20 months (30). While this survival outcome is inferior to that of the early-stage cohort without N3 metastasis, it is markedly superior to the historical upper limit for ES disease, hence underscoring the necessity for definitive treatment in this particular subset of N3 individuals (13). Furthermore, these two divergent prognoses suggest that the current recommendations fail to uniformly account for the variations in N3 disease (31). The primary reason a patient cannot tolerate radiation toxicity is the spatial distribution of the involved lymph nodes. Single-region N3 metastasis (e.g., isolated supraclavicular involvement) exhibits a reasonably compact morphology for the target volume and is frequently amenable to effective local control with cCRT. Conversely, if the disease has disseminated to multiple locations (e.g., ipsilateral supraclavicular metastasis coupled with extensive contralateral mediastinal extension), an aggressive large-field radiation strategy is impractical; furthermore, tumor control is unlikely to be attained, and the risk of significant radiation toxicity, including severe radiation pneumonitis, will be markedly heightened (32). Consequently, treatment selection can no longer be confined to the conventional binary treatment paradigm. Accurate information regarding the number and location of metastatic lesions is increasingly essential for determining local therapy to optimize target volume coverage while safeguarding organs at risk (33). Deep impact of classification controversy on the selection and intensity of systemic therapy (chemotherapy and immunotherapy) Dosimetric issues in local therapy merely represent the surface of the N3 classification controversy, and the ambiguity around the staging boundary has significantly and broadly undermined the strategic optimization of systemic therapy. Currently, the systemic management of SCLC reveals a clear divergence: ES disease (ES-SCLC) has fully embraced first-line standard treatment with chemotherapy combined with immune checkpoint inhibitors (ICIs), as evidenced by the IMpower133 and CASPIAN trials; conversely, the treatment foundation for conventional LS disease (LS-SCLC) remains reliant on platinum-based doublet chemotherapy and localized therapy. Patients with N3 disease situated in the transition zone between the two staging systems may experience variable intensities and durations of systemic therapy. The anatomical distribution of metastatic sites under the N3 classification influences the technical execution of thoracic radiation and suggests the presence of a substantial burden of occult systemic micrometastasis (34,35). Patients with substantial, multi-regional N3 involvement possess extensive lymphatic metastatic networks, which correlate significantly with heightened shedding of circulating tumor cells (CTCs) and an elevated risk of distant organ metastasis. Inappropriately classifying these high-burden patients as LS and providing solely conventional standard-cycle doublet chemotherapy may result in inadequate management of the systemic disease; consequently, patients face an elevated risk of developing lethal early distant metastases in vital organs such as the brain and liver (36). Conversely, for low-burden patients with a solitary N3 metastasis (e.g., isolated contralateral mediastinal involvement), an overly conservative staging strategy and the premature application of ES treatment protocols may preclude these individuals from achieving long-term survival due to the omission of definitive local therapy. The integration of immunotherapy in LS-SCLC, evidenced by the survival advantages of consolidation durvalumab post-chemoradiotherapy in the ADRIATIC trial, has rendered the decision to expedite systemic treatment intensification an increasingly pressing issue. A substantial tumor burden in multi-region N3 disease frequently signifies significant immune exhaustion within the tumor microenvironment. The capacity of this specific sub-population to achieve optimal survival benefits from subsequent consolidation immunotherapy, or the necessity for an upstream adjustment in the therapeutic window (e.g., concurrent or neoadjuvant chemoimmunotherapy), remains undetermined; this represents a critical uncertainty that requires urgent clarification (37). Consequently, the issues related to empirical staging divisions and the quantification of the risk of systemic dissemination based on the number of metastatic sites in an N3 lesion require immediate attention. This approach can enhance the efficacy of the treatment system and ascertain which patients are most likely to benefit from personalized combinations of chemotherapy and immunotherapy. Ultimately, the proven survival benefits of ICIs in the ES setting do not diminish the need for accurate staging; rather, they significantly heighten the clinical risk of misclassification. The urgency now lies not in indiscriminately pushing N3 patients into the “LS” category merely to secure thoracic radiation, but in utilizing precise spatial staging to ensure optimal integration of systemic and local modalities. Specifically, misclassifying high-burden, multi-regional N3 patients as LS could inadvertently deprive them of crucial early, first-line ICI therapy required to combat widespread micrometastasis. Conversely, inappropriately assigning low-burden, single-region N3 patients to the ES chemoimmunotherapy pathway might unnecessarily deny them curative-intent local consolidation radiation. Therefore, the advent of modern chemoimmunotherapy renders the conventional binary staging approach obsolete for the N3 cohort, strongly mandating a spatial burden-driven classification. Comparison of real-world patient survival outcomes based on different staging classifications Although the potential for a favorable prognosis is frequently addressed, the extensive real-world data from major cancer registries [such as the Surveillance, Epidemiology, and End Results (SEER) program and the National Cancer Database (NCDB)] that underpins these conclusions has not been thoroughly utilized due to issues in staging categorization for SCLC (38). Patients exhibiting identical anatomical burdens of N3 metastatic disease are frequently assigned to disparate LS or ES classifications in these databases arbitrarily, owing to variances in the availability of radiation facilities between institutions and the divergent treatment protocols of physicians. This systematic misclassification leads to the recognized “stage migration” issue (sometimes referred to as the Will Rogers effect) in epidemiological survival analysis. Figure 3 illustrates that when multiple N3 patients with minimal metastatic burden (e.g., isolated supraclavicular lymph node involvement) are conservatively categorized as having “ES” disease, their inclusion dilutes the severe prognostic impact of genuine hematogenous visceral metastases (M1), thereby misleadingly elevating the apparent OS of the ES cohort. Conversely, the enhanced capabilities of contemporary radiation result in high-burden multi-region N3 patients being inaccurately classified as “LS”, hence falsely lowering the actual survival curve for the early-stage (N0-N2) LS group (18,39). The mechanism and impact of systematic stage migration (the Will Rogers effect) on survival analysis in stage N3 SCLC. ES, extensive-stage; LS, limited-stage; M1, metastasis 1; N, node; NCDB, National Cancer Database; RT, radiotherapy; SCLC, small cell lung cancer; SEER, Surveillance, Epidemiology, and End Results. Many large-scale dataset comparisons may be erroneous due to two types of errors: inappropriate placement and inconsistent registry data, which undermine the foundation for anatomical alignment. A therapeutically valuable predictive map for N3 disease cannot be derived from ambiguous registry codes; instead, it must be constructed from high-quality retrospective cohorts and meticulously validated against the original imaging data. Resolving the issue of database heterogeneity necessitates a further disaggregation of the N3 category into specific numbers of involved lymph node regions (single-region vs. multi-region) and anatomical sites; this approach will elucidate the true natural history of this high-risk cohort, thereby yielding an accurate prognostic indicator for the precise planning of systemic and local therapies. Integration and future directions: towards a unified SCLC staging consensus Current integration proposals: redefining “LS” based on TNM staging The VALG dichotomous staging method for SCLC has historically been employed for its classification, although this system is predicated on the constraints of radiation technology from the 1950s. The former criteria relied on the concept of “unilateral hemithorax involvement within a single radiation field” and are no longer sufficient for precise prognostication in contemporary oncology across diverse patient populations. The IASLC and the AJCC ninth edition guidelines have strongly advocated for the comprehensive implementation of the anatomical TNM system to create a more biologically stable staging framework for SCLC by objectively quantifying the T, N, and M descriptors. The enhancement of anatomical staging can yield more accurate data for the formulation of therapy strategies for LS-SCLC. Due to the evolution of nodal stratification in lung cancer, refined N descriptors have been established to quantitatively evaluate regional nodal burden. Anatomical classification of “LS” disease to delineate specific anatomical subgroups, independent of conventional technology-dependent radiation portals, has equipped clinicians with a means to discern diverse prognostic trajectories for high-risk, locally advanced subgroups, including those with N3 disease. The AJCC-based redefinition directly enhances medical practice by delineating an early stage (T1-2N0M0) appropriate for definitive surgery; additionally, stratified criteria for local treatment may be established within the N3 subgroup that intersects with the staging boundary (e.g., identifying targets for high-dose radiotherapy). Consequently, this method will be objective and precise, unlike the “technological determinism” observed in the historical VALG classification (40). Future research directions: construction of a multi-modal deep fusion prognostic stratification system and next-generation precision staging for SCLC The primary objective of future research is to create comprehensive and adaptive multi-modal prognostic stratification systems that can thoroughly elucidate the spatio-temporal evolution characteristics of cancers and transcend the limitations of conventional binary classification (41). Due to the significant variability in metastatic burden and biological behavior within the N3 high-risk subgroup, future research should transition from singular anatomical assessments to a comprehensive, multidimensional framework integrating AI with “anatomy-imaging-molecular-immune” data (42). Recent advancements in multi-omics have led to the development of novel multimodal SCLC prediction models with significant clinical translational value, aimed at enhancing prognosis and risk stratification for N3 SCLC. This model must be multi-disciplinary and cross-disciplinary in its base. Figure 4 illustrates that the traditional evaluation method relying solely on linear diameter measurement must be supplanted by deep learning networks, such as graph convolutional networks (GCNs) or three-dimensional convolutional neural networks (3D-CNNs), in the context of panoramic radiomics and spatial burden. These networks can extract high-order texture features and metabolic tumor volumes (MTVs) from both baseline and post-radiotherapy images to accurately quantify spatial distribution heterogeneity and glucose metabolic gradients between “single-region” and “multi-region” metastatic lymph nodes, thereby noninvasively assessing their local invasive potential (43). Proposed multi-modal deep fusion prognostic stratification framework for next-generation precision staging and therapeutic decision-making in stage N3 SCLC. 3D-CNN, three-dimensional convolutional neural network; AI, artificial intelligence; cCRT, concurrent chemoradiotherapy; ctDNA, circulating tumor DNA; GCN, graph convolutional network; IASLC, International Association for the Study of Lung Cancer; LDH, lactate dehydrogenase; MRD, minimal residual disease; MTV, metabolic tumor volume; N3, node 3; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; RT, radiotherapy; SCLC, small cell lung cancer. At the molecular subtyping and minimal residual disease (MRD) monitoring level, concurrently integrate the baseline four major molecular subtypes (SCLC-A, -N, -P, and -Y), characterized by the expression of critical transcription factors (i.e., ASCL1, NEUROD1, POU2F3, and YAP1), to discern intrinsic variations in treatment sensitivity across different subtypes (such as the immune-desert SCLC-N phenotype and the ultra-poor prognostic SCLC-P subtype) to chemoradiotherapy and ICIs. Simultaneously, dynamic clearance rates and mutant allele frequencies of circulating tumor DNA (ctDNA) in the bloodstream during treatment can be utilized to evaluate the magnitude of hematogenous micrometastases (44,45). Longitudinal ctDNA monitoring using ultra-deep sequencing can mitigate the detection limitations of conventional imaging for occult dissemination in multi-regional N3 disease and establish a foundation for early therapeutic intervention or the prolongation of systemic consolidation therapy. At the level of the host systemic immune-metabolic microenvironment, pre-treatment peripheral blood inflammatory indices [such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR)] and nutritional biomarkers [such as lactate dehydrogenase (LDH)] must be meticulously evaluated in conjunction as ancillary indicators of systemic tumor burden and host immunosuppression. To enhance the implementation of algorithms in clinical practice, the next-generation platform will employ sophisticated machine learning approaches, including intermediate fusion, to tackle the issue of absent modalities in real-world multimodal data (46). Non-linear interaction models for the number of involved lymph nodes, radiomic properties, and peripheral blood genetic traits have been established to create personalized survival probability curves (i.e., nomograms). A prognostic model based on digital twins will aid in mitigating the categorization challenge for N3 disease. It can adeptly differentiate between single-region N3 patients exhibiting a low risk of micrometastases and high radiosensitivity to enhance the selection for high-dose definitive cCRT. Conversely, the model effectively identifies high-risk groups exhibiting substantial ctDNA shedding and extensive multi-regional metastases, thereby preventing unnecessary exposure to large-field radiation toxicity and facilitating their referral to neoadjuvant chemoimmunotherapy or more intensive systemic targeted clinical trials. To ascertain the efficacy and viability of this efficient and practicable system, large-scale, multicenter prospective cohort studies, underpinned by standardized biobanks and picture archiving and communication systems (PACS), must be rapidly undertaken (47). Cross-validation on extensive heterogeneous datasets can iteratively enhance both the accuracy and clinical interpretability of these multimodal models. This data-driven methodology will assist the IASLC and associated clinical recommendations in formulating a contemporary precision staging consensus grounded in spatial metastatic burden and molecular profiles. Limitations of the present research While numerous studies have addressed the staging disputes and clinical care challenges of N3 SCLC, certain shortcomings in the existing evidence base must be recognized objectively. The majority of evidence regarding the prognostic significance and treatment outcomes of N3 SCLC is derived from retrospective studies, which are consequently prone to inherent selection bias. For instance, in real-world clinical practice, patients chosen for aggressive definitive cCRT typically have a superior baseline performance status and fewer cardiopulmonary comorbidities compared to those relegated to palliative care. Within the context of a narrative synthesis, this systemic disparity—compounded by the lack of granular comorbidity data in large databases—leaves residual unmeasured confounding. This can inadvertently lead to an overestimation of the survival advantage associated with localized treatment. Secondly, while large epidemiological registries like the SEER database provide robust statistical backing, they lack the necessary anatomical specifics for detailed spatial analysis. These databases inadequately capture detailed data on metastatic disease distribution, failing to differentiate between localized single-region and extensively disseminated multi-region N3 involvement, or to document the exact number of involved lymph node stations; consequently, the depth and accuracy of these large-cohort analyses are considerably diminished. Finally, while the integration of AI (e.g., 3D-CNNs) and multi-omics models (e.g., ultra-deep ctDNA sequencing) represents a promising avenue for next-generation precision oncology, bridging the gap between theoretical modeling and routine clinical application presents formidable practical barriers, particularly in community oncology settings. The successful deployment of 3D-CNNs requires highly standardized, interoperable PACS and substantial computational infrastructure, which are often lacking outside large academic centers. Similarly, ultra-deep sequencing demands stringent pre-analytical protocols and robust biobanking logistics. Furthermore, the clinical feasibility of this framework is currently limited by the high upfront costs of these technologies and a shortage of specialized bioinformatic expertise required to interpret multi-modal data. Therefore, the absence of prospective multicenter validation and rigorous health economic evaluations to prove cost-effectiveness currently precludes their widespread application in routine clinical practice for SCLC. Conclusions The fundamental issue in staging N3 SCLC lies in the outdated “treatment technology-driven” paradigm of conventional clinical practice, while a novel “tumor biology-driven” method has yet to be implemented. For nearly seven decades, the VALG system has fulfilled a practical function under prior conditions and was therefore essential. Nonetheless, the evolution of radiation and advancements in systemic therapies, such as ICIs, have rendered this simplistic classification based on physical borders increasingly inadequate for the requirements of precision oncology in recent times (7). Conversely, while the IASLC TNM staging system delineates specific anatomical sites, it remains deficient in detail; thus, it cannot effectively inform the requisite level of multidisciplinary treatment for the N3 subgroup situated at the interface of localized and disseminated diseases. The conventional assumption that N3 disease constitutes a “homogeneous high-risk cohort” must be reevaluated to surmount this staging obstacle. Clinical studies indicate that the N3 category encompasses distinct biological behaviors and prognostic grades determined by “metastatic burden”. Single-region N3 metastasis, such as isolated supraclavicular or contralateral mediastinal involvement, often allows for effective definitive local therapy and presents a controllable micrometastatic risk. Conversely, multiple sites of N3 metastases signify significant lymphatic dysfunction and present a markedly elevated risk of occult hematogenous dissemination. Consequently, to establish a novel concept of “LS” disease within contemporary staging guidelines for N3 disease, it is imperative to eliminate the “one-size-fits-all” methodology of the current staging system and thoroughly incorporate indicators of spatial heterogeneity, such as the quantity of metastatic regions, into the existing TNM framework. In the future, the criteria for staging SCLC will evolve into a comprehensive system that incorporates anatomical structure, distribution, and extent of metastasis, together with additional data derived from multi-omics analyses. Prior to the comprehensive clinical implementation of established multimodal predictive models, the foremost academic objective is to systematically validate the independent prognostic significance of various metastatic burden subgroups within the N3 category, utilizing high-quality, large-scale real-world cohorts with rigorous imaging verification (48). Clinicians can only choose the most appropriate treatment approach for patients, such as systemic palliative care or high-dose definitive cCRT, after elucidating the true natural history variations of this high-risk population. This will ultimately provide robust, empirical data from large scale real-world patient cohorts to inform future revisions of international lung cancer staging recommendations. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1704/prf